Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Tariquidar Plus Chemotherapy in Treating Children With Relapsed or Refractory Solid Tumors
This study is ongoing, but not recruiting participants.
Study NCT00020514 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: September 5, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Childhood Germ Cell Tumor
Extragonadal Germ Cell Tumor
Kidney Cancer
Liver Cancer
Neuroblastoma
Ovarian Cancer
Sarcoma
Additional conditions recognized in this trial
Carcinoma, Renal Cell
Central Nervous System Neoplasms
Kidney Neoplasms
Liver Neoplasms
Neoplasms
Neoplasms, Germ Cell and Embryonal
Nervous System Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Ovarian Neoplasms
More general conditions related to this trial
Adenocarcinoma
Adnexal Diseases
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Kidney Diseases
Liver Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Nervous System Diseases
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Ovarian Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
filgrastim
docetaxel
doxorubicin hydrochloride
tariquidar
vinorelbine ditartrate
pharmacological study
Additional drug interventions recognized in this trial
Doxorubicin
Vinblastine
Vinorelbine
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
